MOH
Molina Healthcare, Inc.
MOH has the edge over NVO overall, supported by stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
MOH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
MOH's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MOH PE Valuation
MOH has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MOH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
MOH has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MOH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.35 | — |
| Q3 2026 | -$0.60 | -104% |
| Q2 2026 | $0.18 | -99% |
| Q1 2026 | $3.74 | -82% |
| Q4 2025 | $8.92 | -56% |
| Q3 2025 | $16.14 | -18% |
| Q2 2025 | $20.28 | +11% |
| Q1 2025 | $20.70 | +12% |
| Q4 2024 | $20.42 | +8.8% |
MOH has swung to a loss: it lost $0.60 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MOH on earnings quality, reporting a profit while its opponent remains loss making.
MOH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.1B | -3.4% |
| Q2 2026 | $10.9B | -4.8% |
| Q1 2026 | $10.8B | -3.1% |
| Q4 2025 | $11.4B | +8.3% |
| Q3 2025 | $11.5B | +11% |
| Q2 2025 | $11.4B | +16% |
| Q1 2025 | $11.1B | +12% |
| Q4 2024 | $10.5B | +16% |
MOH's revenue grew through 2024 and has held roughly level since: $11.1B last quarter, down 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1% | -0.2 points |
| Q2 2026 | 1.3% | -1.9 points |
| Q1 2026 | 0.8% | -3.1 points |
| Q4 2025 | -1.4% | -5 points |
| Q3 2025 | 1.2% | -3.3 points |
| Q2 2025 | 3.3% | -1.1 points |
| Q1 2025 | 3.9% | -0.4 points |
| Q4 2024 | 3.6% | +0.1 points |
MOH's operating margin was 1% last quarter, about level with the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over MOH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MOH on profitability, with a higher operating margin.
MOH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$196M | -$33M |
| Q2 2026 | -$324M | +$20M |
| Q1 2026 | $1.1B | +528% |
| Q4 2025 | -$297M | -$62M |
| Q3 2025 | -$163M | -119% |
| Q2 2025 | -$344M | -$98M |
| Q1 2025 | $168M | -10% |
| Q4 2024 | -$235M | +$450M |
MOH's free cash flow has turned positive after two years mostly in the red: $238M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over MOH on cash flow, with more consistent year-over-year improvement.
MOH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +200K shares |
| 1 year | -1.9% | -1M shares |
| 3 years | -11% | -6.6M shares |
| 5 years | -12% | -7M shares |
| Available history | -20% | -12.7M shares |
MOH has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $500M |
| Q2 2025 | — |
| Q1 2025 | $500M |
| Q4 2024 | $500M |
MOH hasn't bought back shares in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MOH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -3.3x | Net Cash |
| Q1 2026 | -2.5x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -0.9x | Net Cash |
MOH has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MOH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 55.8 | Neutral |
MOH's weekly RSI is 56 (neutral) and its Stochastic is 56 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MOH PE vs Healthcare Sector
| Metric | MOH | Sector median | Relative |
|---|---|---|---|
| PE | 1,152x | 26x | 4,356% above |
| PE % | 100 | 29 | 71 pts above |
MOH has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over MOH on valuation relative to its sector.
MOH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $202.2 | 3.8% above |
| 20 week MA | $205.7 | 2% above |
| 50 week MA | $183.7 | 14% above |
| 100 week MA | $216.0 | 2.9% below |
| 200 week MA | $271.6 | 23% below |
MOH has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
MOH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $136.1 | $207.1 | +52% |
| 2021 | $207.1 | $316.7 | +53% |
| 2022 | $316.7 | $335.1 | +5.8% |
| 2023 | $335.1 | $361.3 | +7.8% |
| 2024 | $361.3 | $292.2 | -19% |
| 2025 | $292.2 | $164.8 | -44% |
| 2026 YTD | $164.8 | $209.9 | +27% |
MOH has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.